Business Context and Reporting Period
This Form 8-K, filed on November 15, 2022, reports that Chavant Capital Acquisition Corp. (Chavant) entered into a Business Combination Agreement with Mobix Labs, Inc. (Mobix Labs). The transaction is structured as a reverse triangular merger where Chavant will domesticate from the Cayman Islands to Delaware and merge with Mobix Labs. Upon closing, the combined entity will be named Mobix Labs, Inc.
Key Financial Metrics and Transaction Terms
- Valuation: The assumed value of Mobix Labs is set at $235.0 million.
- Transaction Consideration: Mobix Labs shareholders will receive Class A or Class B Common Stock of the combined company based on an exchange ratio derived from the $235.0 million valuation and a $10.00 per share base price.
- Pipe Investment: ACE SO4 Holdings Limited agreed to purchase 3,000,000 shares of Class A Common Stock at $10.00 per share, totaling $30.0 million.
- Minimum Cash Condition: Closing requires at least $50.0 million in available cash, with a minimum of $30.0 million attributed to the PIPE investment.
- Earnout Provisions: Up to 3.5 million additional shares may be issued over a seven-year period if the stock price exceeds $12.50 (1.75 million shares) and $15.00 (additional 1.75 million shares).
- Financial Statements: The filing does not provide specific revenue, profit, or cash flow figures for Mobix Labs. It notes that audited financial statements for fiscal years ended September 30, 2021, and 2022, are required to be delivered by December 15, 2022.
Material Changes and Transaction Structure
The primary material change is the execution of the definitive merger agreement. Key structural elements include:
- Domestication: Chavant will transfer its registration to Delaware immediately prior to closing.
- Capital Structure: Post-merger, Class A and Class B stock will vote together, but Class B shares carry 10 votes per share.
- Extension: Chavant is seeking shareholder approval to extend its deadline to consummate a business combination from January 22, 2023, to July 22, 2023.
- Lock-Up: Founder and legacy equityholders are subject to lock-up periods tied to time (one year) or stock price milestones ($12.00 and $15.00).
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing contains forward-looking statements regarding the anticipated benefits of the transaction, market opportunities, and growth plans, but does not provide specific financial guidance or revenue projections.
Conditions to Closing: The transaction is contingent upon several factors, including:
- Shareholder approval from Chavant and Mobix Labs.
- Receipt of audited financial statements by December 15, 2022.
- Expiration of the HSR Act waiting period.
- Achievement of the $50.0 million minimum cash threshold.
- Nasdaq listing approval for the new securities.
Risks: Significant risks include the potential failure to complete the transaction, inability to raise additional capital, volatility in the stock price, regulatory hurdles (including CFIUS review for the PIPE investor), and the risk that Mobix Labs may never achieve profitability.
Investor Verification Checklist
- Verify the delivery of Mobix Labs' audited financial statements by the December 15, 2022 deadline.
- Confirm the outcome of the Chavant shareholder vote regarding the merger and the extension of the combination deadline.
- Monitor the status of the $30.0 million PIPE investment and the $50.0 million minimum cash condition.
- Review the upcoming Form S-4 Registration Statement for detailed risk factors and financial data.
- Track the status of the Hart-Scott-Rodino (HSR) antitrust review and any other regulatory approvals.